TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00764439
Drug: Nicotine replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy with Standard NRT user direction
Study: NCT00764439
Drug: Nicotine replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy with a Novel NRT user direction
Study: NCT02265276
Drug: Saroglitazar
Normalized name: Saroglitazar
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab Saroglitazar 4 mg oral daily for 24 weeks
Study: NCT01338337
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
Study: NCT02265276
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tab Pioglitazone 30 mg oral daily for 24 weeks
Study: NCT00126633
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00126633
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00754143
Drug: FG-3019
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 2 weeks IV for all infusions
Study: NCT00754143
Drug: FG-3019
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-3019 5 mg/kg every 2 weeks IV for all infusions
Study: NCT00754143
Drug: FG-3019
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
Study: NCT03872453
Drug: Zavegepant
Normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of zavegepant
Study: NCT03872453
Drug: Zavegepant matching placebo
Normalized name: Zavegepant
DrugBank: Zavegepant (DB15688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo matched to zavegepant
Study: NCT02728349
Drug: Chlorogenic acid
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
Study: NCT00679588
Drug: Semuloparin Sodium
Normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study: NCT00679588
Drug: Enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study: NCT01678209
Drug: Atomoxetine arm
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
Study: NCT04305405
Drug: Benralizumab
Normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose will be stratified by body weight at screening: Patients will receive Dose 1 or Dose 2 of Benralizumab administered by SC injection at Day 0 and Weeks 4, 8, and 16, 24, 32, and 40.
Study: NCT00997386
Drug: busulfan, and melphalan, and alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.
Study: NCT01678209
Drug: Methylphenidate arm
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
Study: NCT01521130
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
Study: NCT02851303
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine wean protocol as described in arm description
Study: NCT02851303
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone wean protocol as described in arm description
Study: NCT03546621
Drug: Myrcludex B
Normalized name: Myrcludex B
DrugBank: Myrcludex B (DB14853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg, once daily, subcutaneously
Study: NCT03546621
Drug: Myrcludex-B
Normalized name: Myrcludex B
DrugBank: Myrcludex B (DB14853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, once daily, subcutaneously
Study: NCT03546621
Drug: Myrcludex-B
Normalized name: Myrcludex B
DrugBank: Myrcludex B (DB14853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, once daily, subcutaneously
Study: NCT03546621
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
Study: NCT01454596
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study: NCT01454596
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study: NCT00128739
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03873493
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
Study: NCT00226590
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy.
Study: NCT00226590
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
Study: NCT00226590
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
Study: NCT02434744
Drug: KD026
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed in combination
Study: NCT03873493
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
Study: NCT02434744
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug prescribed by each subject's prescribing physician
Study: NCT00262730
Drug: poly ICLC
Normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg/kg 3x each week (Maintenance cycles)
Study: NCT00262730
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
Study: NCT00095667
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT01170962
Drug: BMS-790052
Normalized name: BMS-790052
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Film coated tablet, Oral, 20 mg, once daily, 24 weeks
Study: NCT01170962
Drug: BMS-790052
Normalized name: BMS-790052
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
Study: NCT01170962
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
Study: NCT01170962
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
Study: NCT03887650
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
Study: NCT02601170
Drug: Hyaluronic Acid Viscosupplementation
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01944007
Drug: Cross-Linked Polyelectrolyte (CLP)
Normalized name: riboflavin 5'-phosphate
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLP was administered orally, in capsules, for 9 consecutive days.
Study: NCT02111447
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion with nasal oxygen
Study: NCT02570542
Drug: Plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
Study: NCT02570542
Drug: carmustine, etoposide, cytarabine, melphalan
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
Study: NCT02111447
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion with an LMA
Study: NCT02111447
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane with an LMA
Study: NCT02111447
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane with an LMA
Study: NCT03367728
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAP and Rectus Sheath Block Injections of Ropivacaine
Study: NCT03626259
Drug: Losartan and Amlodipine
Normalized name: losartan and amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
Study: NCT03626259
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
Study: NCT01577017
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
Study: NCT00857285
Drug: olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olmesartan medoxomil oral tablets, once daily for up to 12 weeks
Study: NCT00857285
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan oral tablets, once daily for up to 12 weeks
Study: NCT00430716
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, 20 mg, tid
Study: NCT00430716
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 1 mg, tid
Study: NCT00430716
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 5 mg, tid
Study: NCT00430716
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral 20 mg, tid
Study: NCT01562808
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single oral administration of aripiprazole
Study: NCT04033562
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine patch will be applied at time of Cesarean delivery for post-operative pain control.
Study: NCT02872116
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT02872116
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT02872116
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT01792700
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01792700
Drug: tripotassium dicitrate bismuthate
Normalized name: tripotassium glycyrrhizinate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01792700
Drug: metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01792700
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01792700
Drug: amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00799201
Drug: Naloxone and Docusate
Normalized name: tilidine and naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
Study: NCT01101399
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy.
Study: NCT01329978
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
Study: NCT01329978
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01329978
Drug: PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
Study: NCT00006269
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006269
Drug: octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03585478
Drug: Latiglutenase
Normalized name: LATIGLUTENASE
DrugBank: Latiglutenase (DB06326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latiglutenase administered orally (daily)
Study: NCT02570191
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 uG in 0.5 mL solution administered once weekly for 48 weeks
Study: NCT02747602
Drug: AC-1204
Normalized name: ONL-1204
DrugBank: ONL-1204 (DB18239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
Study: NCT02747602
Drug: caprylic triglyceride oil (standard breakfast)
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
Study: NCT02747602
Drug: caprylic triglyceride oil (high fat breakfast)
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
Study: NCT02726490
Drug: Glyburide
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
Study: NCT02726490
Drug: Glucovance
Normalized name: Glucovance
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
Study: NCT01693549
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00551876
Drug: MK0653, ezetimibe / Duration of Treatment: 30 Weeks
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01623479
Drug: bimatoprost 0.03%
Normalized name: BIMATOPROST 0.03% SOLN,OPH
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
Study: NCT01682733
Drug: Botulinum toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
Study: NCT01384734
Drug: BMS-663068 400 mg
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study: NCT01384734
Drug: BMS-663068 800 mg
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study: NCT01384734
Drug: BMS-663068 600 mg
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study: NCT01384734
Drug: BMS-663068 1200 mg
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study: NCT01384734
Drug: Raltegravir 400 mg
Normalized name: raltegravir 400 MG
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study: NCT01384734
Drug: Tenofovir 300 mg
Normalized name: tenofovir 300 mg oral tablet
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
Study: NCT01384734
Drug: Ritonavir 100 mg
Normalized name: ritonavir 100 MG
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 100 mg, Once daily, 96 weeks
Study: NCT01384734
Drug: Atazanavir 300 mg
Normalized name: atazanavir 300 MG
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 300 mg, Once daily, 96 weeks
Study: NCT02994173
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Current clinical practice, used as a control in this study
Study: NCT00235820
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg every other week following an 80 mg dose